Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy

BACKGROUND: This was a Japanese subpopulation analysis of MONARCH 2, a double-blind, randomized, placebo-controlled, phase 3 study of abemaciclib plus fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer (ABC). METHODS: Elig...

Descripción completa

Detalles Bibliográficos
Autores principales: Inoue, Kenichi, Masuda, Norikazu, Iwata, Hiroji, Takahashi, Masato, Ito, Yoshinori, Miyoshi, Yasuo, Nakayama, Takahiro, Mukai, Hirofumi, van der Walt, Jan-Stefan, Mori, Joji, Sakaguchi, Sachi, Kawaguchi, Tsutomu, Tanizawa, Yoshinori, Llombart-Cussac, Antonio, Sledge, George W., Toi, Masakazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8354907/
https://www.ncbi.nlm.nih.gov/pubmed/33797023
http://dx.doi.org/10.1007/s12282-021-01239-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8354907/
https://www.ncbi.nlm.nih.gov/pubmed/33797023
http://dx.doi.org/10.1007/s12282-021-01239-8

Ejemplares similares